Prilosec delayed-release capsules and its generics had a market value of $104.5 million for the 12-month period ended January 2021, according to IQVIA.
Astellas is bringing forward a new treatment option for children impacted by neurogenic detrusor overactivity, a bladder dysfunction related to neurological impairment.
CMS approved all eight of the oncology-specific custom QCDR measures developed by The US Oncology Network and submitted as part of McKesson’s 2021 application.
With two new reports, the National Community Pharmacists Association is reflecting on its extensive efforts to help independent pharmacists amid the pandemic, as well as its advocacy efforts on behalf of independent community pharmacists.